Creatine (Herb/Suppl)

Brand and Other Names:amidinosarcosine, creatine citrate, more...creatine monohydrate, creatine phosphate, N-amidinosarcosine
  • Print

Suggested Dosing

Exercise Performance Enhancement

Load: 20 g PO qDay x 5 days

Maint: 2-3 g PO qDay

CHF

20 g PO daily x 5-10 day

Parkinson's Disease

10 g PO qDay

Gyrate Atrophy

1.5 g PO daily

McArdle Disease

Initial: 150 mg/kg/day x 5 day, THEN

60 mg/kg/day PO

Muscular Dystophies

10 g PO daily

Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's Disease)

10 g PO qDay x 12-16 months

Idiopathic Inflammatory Myopathies

20 g/day x 8 days, THEN

3 g/day x 6 months

Amyotrophic Lateral Sclerosis (Orphan)

Orphan indication sponsor

  • Avicena Group, Inc; 228 Hamilton Avenue; Palo Alto, CA 94301

Huntington's Disease (Orphan)

Indicated for treatment of mitochondrial cytopathies

Orphan indication sponsor

  • Avicena Group, Inc; 228 Hamilton Avenue; Palo Alto, CA 94301
Next:

Suggested Uses

Amyotrophic lateral sclerosis, CHF, exercise performance enhancement, gyrate atrophy, McArdle disease, mitochondrial cytopathies, muscle mass builder, muscular dystrophies, neuromuscular disease, rheumatoid arthritis, Parkinson's disease,

Efficacy

Athletic performance: seems to enhance muscle performance during repeated bouts of brief, high-intensity exercise. Does not seem to improve performance in aerobic exercises, or benefit older individuals OR highly trained athletes

CHF: When taken orally improves exercise tolerance but does not affect the ejection fraction. IV creatinine improves cardiac function, including ejection fraction

Gyrate atrophy: seems to slow visual deterioration

McArdle's disease: Preliminary clinical evidence that it can increase exercise capacity & decrease exercise-induced muscle pain

Parkison's disease: Some evidence shows that it can decrease rate of disease progression in early stages

Idiopathic inflammatory myopathies: more evidence is needed to determine effectiveness

Possibly ineffective for amyotrophic lateral sclerosis, rheumatoid arthritis, & schizophrenia

Previous
Next:

Interactions

Interaction Checker

and Creatine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (0)

                  Minor (46)

                  • aceclofenac

                    creatine, aceclofenac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • acemetacin

                    creatine, acemetacin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • aspirin

                    creatine, aspirin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • aspirin rectal

                    creatine, aspirin rectal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • aspirin/citric acid/sodium bicarbonate

                    creatine, aspirin/citric acid/sodium bicarbonate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • benazepril

                    creatine, benazepril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • celecoxib

                    creatine, celecoxib. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • choline magnesium trisalicylate

                    creatine, choline magnesium trisalicylate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • cyclosporine

                    creatine, cyclosporine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • diclofenac

                    creatine, diclofenac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • diflunisal

                    creatine, diflunisal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • enalapril

                    creatine, enalapril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • entecavir

                    creatine, entecavir. Either increases effects of the other by decreasing renal clearance. Minor/Significance Unknown. Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.

                  • etodolac

                    creatine, etodolac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • fenbufen

                    creatine, fenbufen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • fenoprofen

                    creatine, fenoprofen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • flurbiprofen

                    creatine, flurbiprofen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • fosinopril

                    creatine, fosinopril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • ibuprofen

                    creatine, ibuprofen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • ibuprofen IV

                    creatine, ibuprofen IV. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • imidapril

                    creatine, imidapril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • indomethacin

                    creatine, indomethacin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • ketoprofen

                    creatine, ketoprofen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • ketorolac

                    creatine, ketorolac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • ketorolac intranasal

                    creatine, ketorolac intranasal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • lisinopril

                    creatine, lisinopril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • lornoxicam

                    creatine, lornoxicam. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • meclofenamate

                    creatine, meclofenamate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • mefenamic acid

                    creatine, mefenamic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • meloxicam

                    creatine, meloxicam. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • moexipril

                    creatine, moexipril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • nabumetone

                    creatine, nabumetone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • naproxen

                    creatine, naproxen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • oxaprozin

                    creatine, oxaprozin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • parecoxib

                    creatine, parecoxib. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • perindopril

                    creatine, perindopril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • piroxicam

                    creatine, piroxicam. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • quinapril

                    creatine, quinapril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • ramipril

                    creatine, ramipril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • salicylates (non-asa)

                    creatine, salicylates (non-asa). Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • salsalate

                    creatine, salsalate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • sulfasalazine

                    creatine, sulfasalazine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • sulindac

                    creatine, sulindac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • tolfenamic acid

                    creatine, tolfenamic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • tolmetin

                    creatine, tolmetin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  • trandolapril

                    creatine, trandolapril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

                  Previous
                  Next:

                  Adverse Effects

                  Abdominal pain, arrhythmias, cardiac arrest, cardiomyopathy, dehydration, diarrhea, hypertension, ischemic stroke, muscle cramping, nausea, renal dysfunction, rhabdomyolysis, seizures, weight gain

                  Previous
                  Next:

                  Warnings

                  Contraindications

                  Diabetes mellitus, nephrotic syndrome

                  Cautions

                  Concurrent nephrotoxic agents

                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy Category: avoid use

                  Lactation: avoid use

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Metabolism: N/A

                  Excretion: N/A

                  Mechanism of Action

                  Phosphocreatine serves as phosphate donor to generate ATP from ADP

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.